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Background: To examine toxicity and outcomes for patients treated with preoperative chemoradiotherapy (CRT)
for gastric cancer.
Methods: Patients with gastroesophageal (GE) junction (Siewert type II and III) or gastric adenocarcinoma who
underwent neoadjuvant CRT followed by planned surgical resection at Duke University between 1987 and 2009
were reviewed. Overall survival (OS), local control (LC) and disease-free survival (DFS) were estimated using the
Kaplan-Meier method. Toxicity was graded according to the Common Toxicity Criteria for Adverse Events
version 4.0.
Results: Forty-eight patients were included. Most (73%) had proximal (GE junction, cardia and fundus) tumors.
Median radiation therapy dose was 45 Gy. All patients received concurrent chemotherapy. Thirty-six patients (75%)
underwent surgery. Pathologic complete response and R0 resection rates were 19% and 86%, respectively.
Thirty-day surgical mortality was 6%. At 42 months median follow-up, 3-year actuarial OS was 40%. For patients
undergoing surgery, 3-year OS, LC and DFS were 50%, 73% and 41%, respectively.
Conclusions: Preoperative CRT for gastric cancer is well tolerated with acceptable rates of perioperative morbidity
and mortality. In this patient cohort with primarily advanced disease, OS, LC and DFS rates in resected patients are
comparable to similarly staged, adjuvantly treated patients in randomized trials. Further study comparing
neoadjuvant CRT to standard treatment approaches for gastric cancer is indicated.
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Postoperative chemoradiotherapy (CRT), perioperative
chemotherapy (ChT) or postoperative ChT are the current
standards of care for resectable gastric cancer based on
the outcomes of phase III randomized trials [1-4]. While
these strategies have been shown to improve disease-
related outcomes compared to surgery alone, they are
associated with higher rates of treatment-related morbid-
ity. Illustrating this fact, only 64% of patients in the
Intergroup-0116 trial and 42% in the Medical Research
Council Adjuvant Gastric Infusional Chemotherapy
(MAGIC) trial were able to complete their prescribed
treatment courses [1,2].* Correspondence: czito001@mc.duke.edu
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reproduction in any medium, provided the orPreoperative CRT has been established as the primary
treatment modality in other gastrointestinal malignan-
cies, including esophageal [5-8] and rectal cancer [9].
Preoperative CRT has several potential biological and
technical advantages. The presence of intact tumor vas-
culature and oxygenation may enhance responsiveness
to radiotherapy (RT) and systemic therapy. This treat-
ment approach may also sterilize the surgical field, po-
tentially reducing the risk of local tumor dissemination
at resection. Preoperative CRT may also allow design of
smaller and more accurate radiation treatment fields
which could improve treatment tolerance, as well as
identify patients with biologically aggressive disease in
whom surgery should be avoided. In addition, postopera-
tive morbidity following upfront gastrectomy can be sig-
nificant, resulting in the delay or omittance of adjuvant
therapy administration [1,2,10]. Lastly, preoperative CRTtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(R0) resection rates while decreasing the risk of local
tumor recurrence.
There are scant prospective data on clinical outcomes
utilizing preoperative RT for gastric cancer. Trials of
neoadjuvant RT or CRT compared to surgery alone have
shown an overall survival (OS) advantage with preopera-
tive treatment in patients with esophageal and gastric
cardia adenocarcinomas [5,11]. Additionally, several small
phase II trials examining the role of induction ChT fol-
lowed by preoperative CRT for gastric cancer showed en-
couraging rates of pathologic complete response (pCR)
and R0 resections, with acceptable rates of acute and late
toxicity [12-14]. Single institution experiences examining a
neoadjuvant approach for gastric cancer have also been
published [15-17], but data looking at preoperative CRT
without induction ChT are limited. The intent of this study
is to examine our institutional experience with neoadju-
vant CRT for potentially resectable gastric adenocarcin-
oma, evaluating treatment-related toxicity, R0 resection
rates, pCR rates, and disease-related endpoints.
Methods
This Institutional Review Board-approved study included
patients who underwent preoperative CRT for non-
metastatic gastroesophageal (GE) junction and gastric
adenocarcinoma at Duke University Medical Center be-
tween 1987 and 2009. Medical records, pertinent radio-
graphs and RT fields were reviewed to obtain patient
demographics, operative findings, pathology, toxicity, and
to determine local-regional and distant recurrence pat-
terns. Tumor epicenter, GE junction involvement and
tumor (T) and nodal (N) staging were determined using
upper endoscopy, radiographic imaging and/or endo-
scopic ultrasound (EUS).
The institutional policy has been to proceed directly to
resection for early stage gastric cancer in most patients.
In general, patients with locally advanced disease, which
includes those with large primary tumors (≥ T3 tumors),
extensive local-regional nodal involvement or where a
R0 surgical resection may not be feasible initially, are
usually referred for preoperative CRT following evalu-
ation by a multidisciplinary team.
Only Siewert type II/III GE junction and gastric
adenocarcinomas were included in this analysis [18].
Patients with direct tumor extension into adjacent
organs who were still thought to be candidates for re-
section were included. Patients were excluded if the ini-
tial treatment plan was for definitive or palliative CRT,
or if they were found to have metastatic disease during
pre-treatment workup.
Guidelines for preoperative RT planning for gastric
cancer have been previously published and can serve as
a framework for our general approach to treatment fielddesign [19]. External beam RT was delivered via high en-
ergy linear accelerators using 6 MV or 15 MV photons.
Multi-field external beam RT plans were typically designed
to cover the primary tumor and local-regional lymph node
basins. In recent years, a deep inspiratory breath-hold tech-
nique during RT was utilized for patients with significant
tumor motion. Induction, concurrent and adjuvant ChT se-
lection was at the discretion of the treating Medical On-
cologist. Surgical resection typically occurred 4–6 weeks
after CRT completion. The type of surgery depended upon
the treating surgeon’s preference, primary tumor location
and disease extent.
Each patient was staged using the American Joint Com-
mittee on Cancer gastric cancer staging guidelines, 6th edi-
tion. Tumor downstaging was defined as a decrease in
either T stage and/or N stage at the time of resection. Pat-
terns of failure were determined by imaging studies and/or
by findings obtained from diagnostic procedures such as
laparoscopy, laparotomy or computed tomography (CT)-
guided biopsies. Local recurrence was defined as disease
recurrence within the remaining stomach, the operative
bed or local-regional (lower paraesophageal, gastrohepatic,
celiac, superior mesenteric, porta hepatis, and splenic)
lymph nodes basins. Radiographic lymph node recurrences
were defined as lymph nodes ≥ 1 cm on CT which had
increased in size on serial imaging and/or were hypermeta-
bolic on positron emission tomography (PET). Distant
recurrence was defined as any recurrence outside the
aforementioned sites. A consensus opinion was reached by
two authors (J.P. and B.C.) on all suspected cases of local
and distant recurrences as a means to improve accuracy.
The Kaplan-Meier method was used to estimate 3-
year OS, disease-free survival (DFS) and local control
(LC) probabilities with 95% confidence intervals (95%
CI). All disease-related endpoints were calculated from
the preoperative therapy start date. Testing for time to
event differences between groups was performed using
the log-rank (Mantel-Cox) test. Analysis was performed
using SPSS 19.0.0 (IBM Corporation, Somers, NY).
Toxicity was assigned using the National Cancer Insti-
tute Common Toxicity Criteria for Adverse Events ver-
sion 4.0 (CTCAE v4.0). Acute toxicity was defined as
any toxicity from the start of preoperative therapy until
surgery. Late toxicity was defined as any toxicity greater
than 90 days after surgery.
Results
Forty-eight patients were included in the present ana-
lysis. Thirty-three were treated from the year 2000 on-
ward. Median follow-up was 42 months (range 17–144).
Twenty-nine patients (61%) were clinical stage III, and
five patients (10%) were clinical T4 at presentation.
Thirty-one (65%) were clinically node positive. Staging
PET scan was used for 19 patients (40%) and CT scan
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did not receive radiographic staging due to pregnancy at
the time of diagnosis. Thirty-six patients (75%) under-
went baseline EUS prior to CRT. Fourteen patients
underwent pre-treatment laparoscopy or laparotomy.
Thirty-five patients (73%) had proximal tumors, which
include GE junction, cardia, and fundus tumors. Eight
patients (17%) had distal tumors, which include lesions
in the antrum and pylorus. Five patients (10%) had linitis
plastica. Most tumors (n = 25) had poorly differentiated
histology. Patient and tumor characteristics are reported
in Table 1.
Median RT dose was 45 Gy (range 21.6-50.4). All
patients received concurrent ChT and 40 patients (83%)
received fluoropyrimidine-based ChT (Table 2). Four
patients received one cycle of induction fluoropyrimidine-Table 1 Patient and tumor characteristics for patients
undergoing preoperative chemoradiotherapy for gastric
adenocarcinoma (n = 48)














Linitis plastica 5 10











Not specified 6 13
*Proximal tumors involve lesions of the GE junction, cardia or fundus. Distal
tumors include lesions of the antrum and pylorus; †Includes signet ring
6 (n = 17) and mucinous (n = 1) histology.based ChT prior to starting RT. Six patients (13%)
required a treatment break for a median of 4 days (range
2–23). Two patients (4%) were unable to complete the
prescribed CRT treatment course; one patient experienced
a gastric perforation during CRT and the other developed
febrile neutropenia and failure to thrive toward the end of
his CRT course.
Thirty-six patients (75%) underwent surgery. Total
gastrectomy was performed in 13 patients, partial gas-
trectomy in 9 patients and esophagogastrectomy in 14
patients (Table 2). The median number of lymph nodes
sampled was 6 (range 0–34). The R0 resection rate was
86% (n = 31). Overall tumor downstaging was seen in 18
of 28 patients (64%) who had EUS prior to starting pre-
operative therapy. T stage downstaging was seen in 19
patients (68%). Of the 36 patients who underwent sur-
gery, 13 of 22 (59%) who were clinically node positive on
initial evaluation were pathologically node negative. A
pCR was seen in 7 of 36 patients (19%). Nine (25%)
received adjuvant ChT after a R0 resection. Of those,
seven patients received postoperative fluoropyrimidine-
based ChT. Patients did not undergo definitive surgical re-
section due to distant metastases found on restaging scans
or exploratory laparotomy (n = 9), patient refusal (n = 2)
or poor performance status following preoperative CRT
(n = 1). One patient who underwent gastrectomy was
found to have peritoneal carcinomatosis on final path-
ology despite negative intraoperative frozen sections.Table 2 Treatment characteristics for patients undergoing
preoperative chemoradiotherapy for gastric
adenocarcinoma (n = 48)
Characteristic No. %
Concurrent chemotherapy
5-FU or Capecitabine 19 40
5-FU/Carboplatin/Paclitaxel 11 23
5-FU/Cisplatin 6 13





Total gastrectomy 13 27






Not specified 1 2
No surgical resection 12 25
Pepek et al. Radiation Oncology 2013, 8:6 Page 4 of 8
http://www.ro-journal.com/content/8/1/6For the entire cohort, the first site of failure was local-
regional only in 3 patients, synchronous local-regional
and distant in 5 patients and distant only in 19 patients.
One local recurrence occurred in a patient who refused
surgery after completing CRT and developed a gastric
recurrence 26 months later. The most common sites of
distant recurrence were the peritoneal cavity (n = 10)
and liver (n = 8). Three-year actuarial LC and DFS rates
for the entire cohort at 3 years were 72% (95% CI 55–
90) and 30% (95% CI 17–44), respectively. Median OS
was 20 months (range 3–146) and the 3-year OS for the
entire cohort was 40% (95% CI 25–54) (Figure 1).
For the 36 patients who underwent surgery, the first
site of failure was local-regional only in 2 patients, syn-
chronous local-regional and distant in 5 patients, and dis-
tant only in 10 patients. For the 7 patients who achieved
pCR, there were no local recurrences and three distant
recurrences (liver (n = 2) and brain (n = 1)). Three-year ac-
tuarial LC and DFS rates for patients who underwent sur-
gery were 73% (95% CI 55–91) and 41% (95% CI 24–57),
respectively. The 3-year OS rate for patients who under-
went surgery was 50% (95% CI 33–68) (Figure 2). Median
OS for patients who completed combined modality ther-
apy followed by surgical resection was 37 months. Those
who completed CRT but did not undergo surgery had a
median OS of 6 months. There was no difference in OS at
3 years for patients who achieved a pCR versus those whoFigure 1 Kaplan-Meier estimates for overall survival, disease-free survdid not (57% vs. 43%, p = 0.60). However, in patients
achieving R0 resection (compared to R1 resection), there
were statistically significant improvements at 3 years in
OS (54% vs. 0%, p = .045) and DFS (42% vs. 0%, p = 0.002).
Acute grade 3–4 CRT-related toxicity is listed in
Table 3. Two patients (6%) died within 30 days following
surgery. One died due to gastrointestinal hemorrhage
and the other died from postoperative sepsis. Four
patients (11%) experienced a postoperative anastomotic
leak that required intervention; an additional 3 patients
(8%) had asymptomatic anastomotic leaks which were
managed conservatively. Table 4 lists toxicities at least
3 months following surgery. All late grade 3 gastrointes-
tinal toxicity was due to prolonged feeding tube depend-
ence stemming from GI dysmotility (n = 4) or dysphagia
requiring esophageal dilation (n = 9). The actuarial rate
of chronic (≥ 3 months) dysphagia requiring esophageal
dilation was 21% at 1 year (median time to dilation
5.7 months). There was one late grade 5 event stemming
from complications following gastric perforation occur-
ring during CRT.
Discussion
The primary treatment modality for patients with localized
gastric cancer is surgery. However, rates of both local and
distant recurrence remain high following curative intent
resection alone [20-23]. Several small prospective studiesival and local control, all patients.
Figure 2 Kaplan-Meier estimates for overall survival, disease-free survival and local control for patients undergoing surgery.
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tive CRT for potentially resectable gastric cancer [12-14].
Single institution experiences using either preoperative
ChT and/or CRT have also been described [15-17], al-
though the data examining a neoadjuvant approach in gas-
tric cancer remains limited. Our institution has favored an
approach of neoadjuvant CRT without induction ChT for
patients primarily with locally advanced disease, promptingTable 3 Grade 3–4 chemoradiotherapy-associated acute
toxicity (n = 48)
Toxicity Grade 3-4
n %











Perforation 1 2the present analysis of treatment-related toxicities and out-
comes for this group of patients.
Preoperative CRT was well tolerated in our series, with
96% of patients able to complete the prescribed treat-
ment course and only six patients requiring treatment
break. Similarly, in a pilot study from Lowy et al., 96%
(23 of 24 patients) were able to complete neoadjuvant
fluoropyrimidine-based CRT without treatment break
[24]. These studies are in contrast to results from the
Intergroup-0116 trial where only 64% of 281 patients
were able to complete the prescribed postoperative
protocol [1]. Improved compliance and acceptable acute
toxicity rates with neoadjuvant CRT seen in our series
may be due in part to smaller RT treatment fields and/
or improved performance status at the time of CRT
compared to the post-gastrectomy setting.
Acute and late toxicity data assessing neoadjuvant
CRT for gastric cancer are limited [12,13,24]. In our
series, four surgical patients (11%) experienced symp-
tomatic anastomotic leak requiring intervention, which
is similar to rates seen in a pilot study of preoperative
CRT [24] and a Dutch Gastric Cancer Group trial evalu-
ating extended lymphadenectomy [25] for gastric cancer.
With respect to late toxicity, 5% of patients in RTOG
9904 evaluating preoperative CRT experienced late grade
3 toxicity [12], which is lower than in our series. Most
occurrences of late grade 3 toxicities in our cohort were
Table 4 Long-term (≥ 3 month) toxicity for patients
undergoing surgery (n = 36)
Toxicity Grade 2 Grade 3 Grade 4 Grade 5
Worst Overall 3 (8%) 12 (33%) 0 1 (2%)
Stomach/Bowel 3 (8%) 4 (11%) 0 1 (2%)
Esophagus 1 (3%) 9 (25%) 0 0
Musculoskeletal 1 (3%) 0 0 0
Other 1 (3%) 0 0 0
Percentages are in parentheses.
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quiring esophageal dilation at one year. It is possible that
these comparative differences may be attributable to var-
iations in scoring toxicity between studies.
Thirty-day postoperative mortality was 6% in our ana-
lysis, which is consistent with previously reported mor-
tality rates examining neoadjuvant CRT for gastric
[14,24] and esophageal malignancies [5,8,26]. The influ-
ence of preoperative CRT on perioperative mortality
remains debatable when compared to upfront surgical
resection. In the POET trial by Stahl et al., preoperative
CRT was associated with a non-significant increase in
postoperative mortality compared to a ChT alone ap-
proach [27]. However, the CROSS trial showed no differ-
ence in operative mortality for patients who received
preoperative CRT versus those undergoing surgery alone
for esophageal cancer [8]. Similarly, previously published
data from our institution suggested that induction ther-
apy for esophagogastrectomy patients was not associated
with an increased risk of surgical mortality on multivari-
able analysis [28].
Historically, the inability to achieve a curative resection
with surgery alone for gastric cancer is high and portends
a poor prognosis [29]. One randomized trial demonstrated
an improvement in OS for gastric cancer patients achiev-
ing R0 resection [30]. Additionally, the MAGIC trial
showed a statistically significant improvement in R0 resec-
tions among surgical patients who received preoperative
ChT [2]. Using these trials as guides, it can be inferred that
a preoperative approach may improve disease-related out-
comes. The R0 resection rate for those undergoing surgery
in our series (86%) is comparable to prospective studiesTable 5 Comparison of present series to prospective preoper
Series Patients (n) R0 resec
M.D. Anderson (Lowy et al.) 24 9
Multi-institutional (Ajani et al.) 33 8
M.D. Anderson(Ajani et al.) 41 8
RTOG 9904 (Ajani et al.) 43 7
Current series (Pepek et al.) 48 8
* Percentages are based on number of patients who underwent surgery after preop
** Numbers in parentheses are actuarial data in years.utilizing neoadjuvant CRT for gastric cancer [12-14,24].
This is particularly encouraging as many patients had lo-
cally advanced, potentially unresectable disease at presen-
tation with accompanying adverse histologic features,
including signet ring cell histology and linitis plastica [31].
Our data underscore the importance of achieving a R0 re-
section, with 3-year OS of 54% compared to 0% for those
undergoing R1 resection.
Several series have demonstrated that pathologic response
to CRT is predictive of patient outcomes [12,13,15-17].
Three phase II trials from Ajani et al. showed pCR rates ran-
ging from 20% to 30% with the use of induction CT fol-
lowed by concurrent CRT, [12-14] with associated
improvements in OS and DFS in these patients. A series
from M.D. Anderson reported a 23% pCR rate with either
induction ChT followed by concurrent CRT or concurrent
CRT for both GE junction and gastric malignancies. In this
study, pCR was the only statistically significant predictor of
LC based on multivariable analysis [15]. Similarly, another
recent report showed lower recurrence rates and greater
OS, DFS and relapse-free survival in the pCR group versus
the non-pCR group [16]. The pCR rate in the present ana-
lysis appears consistent with other series, but did not trans-
late into improved OS in our cohort. Although LC was
100% in the pCR group, the low absolute numbers of
patients and high distant failure rates potentially diluted any
impact of pCR within our study. Nevertheless, most data
suggest that gastric cancer patients who have a pCR have
more favorable outcomes. Data examining preoperative ChT
alone for resectable gastric cancer show pCR rates of only
0-7% [2,32,33], suggesting that the addition of RT with
concurrent ChT may improve tumor response and
disease-related endpoints compared to a ChT alone ap-
proach. This was demonstrated in a recent randomized
trial evaluating preoperative ChT versus CRT in GE junc-
tion cancer patients [27].
While the number of events are small, our data sug-
gest that both local and distant recurrences are still
problematic despite aggressive combined modality ther-
apy. Most patients recurred distantly as their first site of
recurrence, which is concordant with other published
series [12,16]. The actuarial local recurrence rate in our
cohort was 28% for all patients and 27% in the subset ofative chemoradiotherapy trials in gastric cancer
tion (%)* pCR rate (%)* Overall survival (%)**
5 11 N/A
2 36 54 (2)
0 20 N/A
5 31 72 (1)
6 19 40 (3)
erative chemoradiotherapy.
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are slightly higher than expected, even for those with a
R0 resection, this may be attributable to the aggressive
and locally advanced nature of disease seen in our co-
hort as well as variability in RT treatment field design
over the study period. Optimizing ChT regimens, includ-
ing the use of novel conventional and targeted biologic
therapies, may be a potential way to improve pathologic
response and R0 resection rates, reduce distant recur-
rences, and improve survival rates in future trials exam-
ining preoperative CRT. Advancements in pre-treatment
staging are also critical to better select appropriate surgi-
cal candidates. Two such examples include PET/CT,
which may improve accuracy for preoperative staging
[34], and staging laparoscopy, which may identify the ap-
proximately 20-40% of patients with localized disease
based on preoperative CT but who demonstrate periton-
eal metastases at laparoscopy [35,36].
The present study has a number of limitations inher-
ent to retrospective series. First, our cohort is limited by
small patient numbers, resulting in few total events and
wide confidence intervals for actuarial data. Second,
clinical and pathological data were not collected pro-
spectively which allows for selection bias to be intro-
duced. Furthermore, local and distant recurrences were
not always pathologically confirmed, with most diag-
nosed by CT imaging, potentially underestimating local
and distant recurrences within the study. During sur-
gery, a median of 6 lymph nodes were sampled which
may be insufficient for adequate dissection of regional
lymph nodes. However, the limited extent of lymph node
dissection appears consistent with national data from
the Surveillance, Epidemiology, and End Results (SEER)
cancer registry which showed that a median of 8 lymph
nodes were sampled during gastric cancer resection,
with only 25% of patients having 15 or more lymph
nodes examined [37]. Additionally, the impact of pre-
operative CRT on lymph node harvest in gastric cancer
is not well defined. Nevertheless, a more extensive dis-
section may have improved disease-specific outcomes in
our cohort given the potential for understaging with a
limited lymph node sampling [37,38].
Despite these limitations, it is important to emphasize
that many of these patients were referred for initial CRT
due to concern for unresectability. This may result in a
negative selection bias for patients who are referred for
RT in this series, potentially leading to worse treatment-
related outcomes. Even with these aggressive malignan-
cies, R0 resection rates, pCR and survival outcomes are
comparable to prospective series utilizing neoadjuvant
CRT for gastric cancer (Table 5). Importantly, patients
with rapidly progressive disease or with occult meta-
static disease at presentation were spared the morbidity
associated with surgical resection with this treatmentapproach. In our study, 25% of patients did not undergo
gastrectomy due to the reasons stated above. Thus, we
contend that neoadjuvant CRT can be a feasible and ef-
fective selection tool to identify patients with locally
advanced disease who could proceed to surgery.
In conclusion, preoperative CRT for gastric cancer is
reasonably well tolerated with acceptable rates of peri-
operative morbidity and mortality. R0 resection rates
and pCR are encouraging with this treatment strategy.
Despite evaluating a cohort with primarily advanced dis-
ease and adverse histologic features, LC, DFS and OS
rates in resected patients are comparable to similarly
staged, adjuvantly treated patients in randomized trials.
Further study comparing neoadjuvant CRT to standard
treatment approaches for gastric cancer is warranted.
Presented at the 52th Annual Meeting of the American
Society of Radiation Oncology, San Diego, California,
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